Epidemiology, health policy and outcomes
Eric Gapud, MD, PhD
U.S. Food and Drug Administration
BETHESDA, MD, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Nadia Habal, MD
FDA
McLean, VA, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Anil Rajpal, MD, MPH
FDA
Rockville, MD, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Timely communication of evolving safety information is a critical element in the ability of practitioners to provide the best care for their patients with rheumatic diseases. The speakers and panel will discuss the FDA’s approach to ensuring the availability of safe and effective drugs and highlight new initiatives. This session will provide an update on new and evolving topics in patient safety, including the regulatory considerations. Case studies or examples of interesting regulatory issues or safety issues will be presented.
Speaker: Eric Gapud, MD, PhD – U.S. Food and Drug Administration
Speaker: Nadia Habal, MD – FDA
Speaker: Anil Rajpal, MD, MPH – FDA